Table 2.
Mean baseline, week 24, and change in clinical and biochemical measures.
| Placebo (n = 11) | 2 gm/day Curcumin (n = 9) | 4 gm/day Curcumin (n = 10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| baseline | week 24 | change | baseline | week 24 | change | baseline | week 24 | change | ||
| MMSE | 23.2 (2.3) | 22.7 (2.3) | -0.45 (2.6) | 21.4 (3.2) | 19.6 (3.9) | - 1.89 (2.6) | 22.8 (3.4) | 19.9 (3.0) | -2.90 (2.0) | P = 0.08 |
| ADAS-Cog | 18.2 (4.9) | 20.4 (7.1) | 2.2 (5.0) | 20.9 (7.4) | 27.2 (11.7) | 6.3 (8.1) | 19.3 (3.4) | 22.4 (4.4) | 3.1 (3.4) | P = 0.26 |
| NPI total | 8.5 (12.4) | 10.3 (14.3) | 1.8 (10.0) | 8.9 (9.6) | 11.0 (15.8) | 2.1 (10.1) | 11.7 (16.9) | 6.9 (5.6) | -4.8 (14.7) | P = 0.35 |
| ADCS-ADL | 66.7 (3.6) | 60.6 (9.5) | -4.9 (7.6) | 60.3 (10.9) | 53.1 (15.4) | -6.3 (6.8) | 61.0 (8.4) | 56.2 (9.4) | -3.4 (6.5) | P = 0.72 |
| Plasma Aβ42 (pg/mL) | 28.7 (11.2) | 31.4 (13.5) | 2.7 (4.5) | 25.3 (8.2) | 25.3 (10.4) | 0.0 (3.3) | 29.6 (4.8) | 30.5 (6.7) | 0.9 (3.5) | P = 0.98 |
| Plasma Aβ40 (pg/mL) | 234.2 (60.3) | 220.4 (74.9) | -13.8 (64.9) | 239.4 (41.8) | 226.1 (27.3) | -13.3 (39.6) | 224.9 (38.5) | 219.4 (57.6) | -18.9 (58.1) | P = 0.29 |
| CSF Aβ42 (pg/mL) | 150.7 (26.2) | 157.5 (32.0) | 6.8 (19.8) | 150.2 (35.0) | 159.2 (30.8) | 9.0 (17.0) | 159.1 (27.2) | 168.8 (30. 7) | 9.7 (30.8) | P = 0.96 |
| CSF Total tau (pg/mL) | 110.9 (75.9) | 114.7 (82.9) | 3.8 (27.9) | 95.8 (31.5) | 95.9 (23.2) | 0.1 (14.5) | 146.0 (78.0) | 149.3 (81.1) | 3.3 (38.3)) | P = 0.97 |
| CSF Phospho-tau (pg/mL) | 48.6 (18.8) | 51.3 (19.3) | 2.7 (6.4) | 49.8 (28.3) | 55.6 (40.5) | 5.8 (13.9) | 61.0 (30.7) | 65.8 (32.9) | 4.8 (12.2) | P = 0.83 |
| CSF F2-IsoPs (ng/mL) | 0.035 (0.005) | 0.029 (0.009) | -0.006 (0.008) | 0.023 (0.005) | 0.022 (0.005) | -0.001 (0.005) | 0.030 (0.008) | 0.031 (0.013) | 0.001 (0.009) | P = 0.08 |
CSF analyses are for 10 subjects in the placebo group, seven in the 2 gm/day group, and eight in the 4 gm/day group. Two subjects in the 4 gm/day group were lacking valid plasma Aβ40 levels and ADCS-ADL data was missing on one subject in each group. Aβ, amyloid beta; ADAS-Cog, Alzheimer's Disease Assessment Scale - Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study - Activities of Daily Living; CSF, cerebrospinal fluid; NPI, Neuropsychiatric Inventory; p-tau, phosphorylated tau.